Certain mutations or alterations in tumor-related genes, including Wnt/β-catenin pathway alterations and TP53 gene mutations, have been associated with resistance to ICIs and the development of an immunosuppressive tumor microenvironment (TME) in advanced HCC. Here, TP53 is linked to neoplasm.